Another study demonstrated that knockdown of VIRMA could decrease the stability of CCAT1 and CCAT2 lncRNA in an m6A-dependent manner to regulate MYC transcription, promoting progression of prostate cancer [58]. Here, VIRMA is linked to prostate cancer.